Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough pancreatic cancer: experimental combo tested

NCT ID NCT07235202

Disease control Sponsor: Shenzhen Majory Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults with this type of cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic PDAC, progressed after only one prior line of systemic therapy. * At least one measurable lesion per RECIST v1.1. * ECOG Performance Status of 0-1. * Life expectancy \>3 months. * Adequate organ and marrow function as defined by laboratory parameters. * Voluntarily sign the informed consent form. Exclusion Criteria: * Known hypersensitivity to MR001 or similar monoclonal antibodies. * Requirement for systemic immunosuppressive therapy within 14 days before first dosing. * Uncontrolled active infections or concurrent malignancies. * Not adequately controlled active brain metastases or leptomeningeal metastasis. * Clinically significant cardiovascular, renal, or hepatic disorders. * Pregnant or breastfeeding women. * Any other circumstances which the investigator considers may increase risks to subjects or interfere with the results of the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma (PDAC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic ductal adenocarcinoma (PDAC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tsinghua Changgung Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102218, China

  • Harbin Medical University Cancer Hospital

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, 150081, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510000, China

  • The First Hospital of Jilin University

    NOT_YET_RECRUITING

    Changchun, Jilin, 130015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.